Literature DB >> 31910110

Upregulation of HLA Class I and Antiviral Tissue Responses in Hashimoto's Thyroiditis.

Therese Weider1,2, Sarah J Richardson3, Noel G Morgan3, Trond H Paulsen4, Knut Dahl-Jørgensen5,2, Sara Salehi Hammerstad5.   

Abstract

Background: Hashimoto's thyroiditis (HT) is a common autoimmune disease of unknown origin. However, viral infections have been implicated as triggers for autoimmunity. Human leukocyte antigen (HLA) class I presents antigens to circulating immune cells and plays a crucial role in the defense against viral infections. This study aimed to investigate the presence of enterovirus and HLA class I expression in one of the largest HT thyroid tissue cohorts to date. In addition, viral receptors and viral immune response proteins were examined.
Methods: Thyroid tissue samples from 46 HT patients were obtained using core needle biopsy. Thyroid tissue collected during neck surgery for other reasons than thyroid autoimmunity served as controls. Standard immunohistochemistry on formalin-fixed, paraffin-embedded tissue samples were used to detect HLA class I, enteroviral capsid protein 1 (VP1), and coxsackie and adenovirus receptor (CAR) in thyroid cells. A subset of the samples was examined with combined immunofluorescence staining for signal transducer and activator of transcription 1 (STAT1) and protein kinase R (PKR).
Results: Significantly more HLA class I-positive samples were found in the HT group (31 out of 46 [67.4%]) than in the control group (5 out of 24 [20.8%]) (p < 0.001). Moreover, the semiquantitative score assessing the grade of HLA class I expression was significantly higher in the HT group (3.9 ± 3.1) than in the control group (0.5 ± 0.9) (p < 0.001). In addition, STAT1 was colocalized with HLA class I, and PKR and VP1 were also found and were colocalized together. VP1 was detected in both controls and the HT samples, with slightly more VP1+ thyroid cells in the HT samples (20.1% ± 16.4%) than in controls (14.9% ± 10.5%). Finally, the presence of CAR in thyroid cells was confirmed.
Conclusion: The current study confirmed that HLA class I hyperexpression is a defining feature of HT. Thyroid cells express CAR, thus making them susceptible to enterovirus infection. The colocalization of HLA class I with STAT1 and VP1 with PKR indicates an intracellular, antiviral host response. These findings support the concept of a firm link between viral infection and autoimmune thyroid diseases.

Entities:  

Keywords:  Hashimoto disease; STAT1 transcription factor; autoimmune thyroiditis; coxsackie adenovirus receptor; histocompatibility antigens class I; virus diseases

Mesh:

Substances:

Year:  2020        PMID: 31910110     DOI: 10.1089/thy.2019.0607

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  4 in total

1.  Potential mechanism prediction of Cold-Damp Plague Formula against COVID-19 via network pharmacology analysis and molecular docking.

Authors:  Lin Han; Xiu-Xiu Wei; Yu-Jiao Zheng; Li-Li Zhang; Xin-Miao Wang; Hao-Yu Yang; Xu Ma; Lin-Hua Zhao; Xiao-Lin Tong
Journal:  Chin Med       Date:  2020-07-30       Impact factor: 5.455

2.  Hormonal Regulation of the MHC Class I Gene in Thyroid Cells: Role of the Promoter "Tissue-Specific" Region.

Authors:  Cesidio Giuliani; Sara Verrocchio; Fabio Verginelli; Ines Bucci; Antonino Grassadonia; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-06       Impact factor: 5.555

3.  High Prevalence of Common Human Viruses in Thyroid Tissue.

Authors:  Therese Weider; Angelo Genoni; Francesco Broccolo; Trond H Paulsen; Knut Dahl-Jørgensen; Antonio Toniolo; Sara Salehi Hammerstad
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

4.  HLA Class I Upregulation and Antiviral Immune Responses in Graves Disease.

Authors:  Therese Weider; Sarah J Richardson; Noel G Morgan; Trond H Paulsen; Knut Dahl-Jørgensen; Sara Salehi Hammerstad
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.